Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF +8.04%78 Capex-to-Operating-Cash-Flow is 0.02 as of Dec. 2025, which is 88% below its 10-year median of 0.16. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.96 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 64 Medical Distribution companies, Sinopharm Group Co ranks better than 75% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Sinopharm Group Co (OTCPK:SHTDF) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Sinopharm Group Co Capex-to-Operating-Cash-Flow Related Terms
Sinopharm Group Co Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Capex-to-Operating-Cash-Flow Chart
SHTDF vs MCK, COR, CAH: Capex-to-Operating-Cash-Flow Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Capex-to-Operating-Cash-Flow vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.02 mean?
Sinopharm Group Co (SHTDF) has a Capex-to-Operating-Cash-Flow of 0.02 as of Dec. 2025. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Sinopharm Group Co and its competitors. This is 88% below median its historical median of 0.16. Over the past decade, Sinopharm Group Co's Capex-to-Operating-Cash-Flow has ranged from 0.11 to 0.93. According to the industry distribution chart, Sinopharm Group Co ranks #16 out of 64 companies in the Medical Distribution industry, placing it in the top 25%.
Is Sinopharm Group Co's Capex-to-Operating-Cash-Flow too high?
Sinopharm Group Co's current Capex-to-Operating-Cash-Flow of 0.02 is 88% below median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.93. The Medical Distribution industry median Capex-to-Operating-Cash-Flow is 0.31. Sinopharm Group Co's value of 0.02 is 93.4% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #16 out of 64 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Capex-to-Operating-Cash-Flow compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #16 out of 64 companies for Capex-to-Operating-Cash-Flow. This places Sinopharm Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Cash-Flow is 0.31. Sinopharm Group Co's value of 0.02 is 93.4% below this benchmark. Historically, Sinopharm Group Co's own Capex-to-Operating-Cash-Flow has ranged from 0.11 to 0.93 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 0.31, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Medical Distribution company?
The median Capex-to-Operating-Cash-Flow among Medical Distribution companies is 0.31, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Capex-to-Operating-Cash-Flow of 0.02 is 93.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Capex-to-Operating-Cash-Flow is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Capex-to-Operating-Cash-Flow is 0.02, which is 88% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.96, compared to a current price of $2.15 — trading 27.4% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.02, which is 88% below median its 10-year median of 0.16 and 93.4% below the Medical Distribution industry median of 0.31. Sinopharm Group Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Capex-to-Operating-Cash-Flow is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.15 is trading 27.4% below its estimated GF Value™ of $2.96.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Capex-to-Operating-Cash-Flow: 0.02 (88% below median its 10-year median of 0.16)
GF Value™: $2.96 vs. price of $2.15 (27.4% below fair value)
Industry Position: 93.4% below the Medical Distribution median (#16 of 64)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
